172 related articles for article (PubMed ID: 21082235)
1. Identification of CD133(-)/telomerase(low) progenitor cells in glioblastoma-derived cancer stem cell lines.
Beier F; Beier CP; Aschenbrenner I; Hildebrandt GC; Brümmendorf TH; Beier D
Cell Mol Neurobiol; 2011 Apr; 31(3):337-43. PubMed ID: 21082235
[TBL] [Abstract][Full Text] [Related]
2. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin.
Lottaz C; Beier D; Meyer K; Kumar P; Hermann A; Schwarz J; Junker M; Oefner PJ; Bogdahn U; Wischhusen J; Spang R; Storch A; Beier CP
Cancer Res; 2010 Mar; 70(5):2030-40. PubMed ID: 20145155
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57.
Zhu X; Prasad S; Gaedicke S; Hettich M; Firat E; Niedermann G
Oncotarget; 2015 Jan; 6(1):171-84. PubMed ID: 25426558
[TBL] [Abstract][Full Text] [Related]
5. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
Liu Q; Nguyen DH; Dong Q; Shitaku P; Chung K; Liu OY; Tso JL; Liu JY; Konkankit V; Cloughesy TF; Mischel PS; Lane TF; Liau LM; Nelson SF; Tso CL
J Neurooncol; 2009 Aug; 94(1):1-19. PubMed ID: 19468690
[TBL] [Abstract][Full Text] [Related]
6. CD133 is essential for glioblastoma stem cell maintenance.
Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous phenotype of human glioblastoma: in vitro study.
Denysenko T; Gennero L; Juenemann C; Morra I; Masperi P; Ceroni V; Pragliola A; Ponzetto A; Melcarne A
Cell Biochem Funct; 2014 Mar; 32(2):164-76. PubMed ID: 23836332
[TBL] [Abstract][Full Text] [Related]
8. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
[TBL] [Abstract][Full Text] [Related]
9. Side population rather than CD133(+) cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells.
Zhou J; Wang H; Cannon V; Wolcott KM; Song H; Yates C
Mol Cancer; 2011 Sep; 10():112. PubMed ID: 21917149
[TBL] [Abstract][Full Text] [Related]
10. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.
Bidlingmaier S; Zhu X; Liu B
J Mol Med (Berl); 2008 Sep; 86(9):1025-32. PubMed ID: 18535813
[TBL] [Abstract][Full Text] [Related]
11. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.
Silva IA; Bai S; McLean K; Yang K; Griffith K; Thomas D; Ginestier C; Johnston C; Kueck A; Reynolds RK; Wicha MS; Buckanovich RJ
Cancer Res; 2011 Jun; 71(11):3991-4001. PubMed ID: 21498635
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53.
Park EK; Lee JC; Park JW; Bang SY; Yi SA; Kim BK; Park JH; Kwon SH; You JS; Nam SW; Cho EJ; Han JW
Cell Death Dis; 2015 Nov; 6(11):e1964. PubMed ID: 26539911
[TBL] [Abstract][Full Text] [Related]
13. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.
Ma S; Chan KW; Lee TK; Tang KH; Wo JY; Zheng BJ; Guan XY
Mol Cancer Res; 2008 Jul; 6(7):1146-53. PubMed ID: 18644979
[TBL] [Abstract][Full Text] [Related]
14. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations.
Yan X; Ma L; Yi D; Yoon JG; Diercks A; Foltz G; Price ND; Hood LE; Tian Q
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1591-6. PubMed ID: 21220328
[TBL] [Abstract][Full Text] [Related]
15. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma cancer stem cells--from concept to clinical application.
Stopschinski BE; Beier CP; Beier D
Cancer Lett; 2013 Sep; 338(1):32-40. PubMed ID: 22668828
[TBL] [Abstract][Full Text] [Related]
17. A2B5 cells from human glioblastoma have cancer stem cell properties.
Tchoghandjian A; Baeza N; Colin C; Cayre M; Metellus P; Beclin C; Ouafik L; Figarella-Branger D
Brain Pathol; 2010 Jan; 20(1):211-21. PubMed ID: 19243384
[TBL] [Abstract][Full Text] [Related]
18. Partial biological characterization of cancer stem-like cell line (WJ(2)) of human glioblastoma multiforme.
Wang J; Wang X; Jiang S; Lin P; Zhang J; Wu Y; Xiong Z; Ren JJ; Yang H
Cell Mol Neurobiol; 2008 Nov; 28(7):991-1003. PubMed ID: 18350379
[TBL] [Abstract][Full Text] [Related]
19. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
Liu G; Yuan X; Zeng Z; Tunici P; Ng H; Abdulkadir IR; Lu L; Irvin D; Black KL; Yu JS
Mol Cancer; 2006 Dec; 5():67. PubMed ID: 17140455
[TBL] [Abstract][Full Text] [Related]
20. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.
Fan X; Khaki L; Zhu TS; Soules ME; Talsma CE; Gul N; Koh C; Zhang J; Li YM; Maciaczyk J; Nikkhah G; Dimeco F; Piccirillo S; Vescovi AL; Eberhart CG
Stem Cells; 2010 Jan; 28(1):5-16. PubMed ID: 19904829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]